INTRODUCTION
Human enteroviruses (EVs) are members of the family Picornaviridae and are classified into seven species, EV-A to -D and human rhinovirus A (HRV-A) to HRV-C. They cause a wide variety of disease from mild infections to severe cases of meningitis or myocarditis. These viruses are widespread, with multiple genotypes co-circulating and causing outbreaks with new or more virulent types. Treatment options for severe EV infections are limited. Based on the humoral responsiveness of EV infection, intravenous IG (IVIg) is often given in severe cases. However, the clinical outcome varies and relies on the presence of the neutralizing Igs within a given batch (Wildenbeest et al., 2012) . There is currently no antiviral drug available to treat EV-infected patients. In the 1990s, pleconaril was developed to combat rhinovirus infections (Hayden et al., 2003; Romero, 2001; Rotbart, 2002; Rotbart & Webster, 2001) and it is the only anti-enteroviral drug that reached phase III clinical trials. Pleconaril is a capsid inhibitor designed to dock within a hydrophobic pocket formed by the capsid proteins VP1, VP3 and VP2. The compound leads to stiffening of the capsid structure, preventing RNA release into the cell (Pevear et al., 1989) . Pleconaril has been used as treatment on a compassionateuse basis in neonates and immunodeficient patients with severe EV infections (reviewed by Wildenbeest et al., 2012) . Results on the clinical outcome varied considerably from complete recovery to fatalities. Data on resistance occurrence and development have only been provided in pleconaril trials against HRV (Ledford et al., 2004 (Ledford et al., , 2005 Pevear et al., 2005) . Remarkably, the reason for these differences in responses was never investigated by means of typing and testing the in vitro susceptibility of isolated virus strains. The failure of EVs to react to pleconaril could have been attributed to the drug-induced emergence of resistance but also to infection with a strain that is naturally or intrinsically resistant to pleconaril, as has been described for coxsackievirus (CV) B3 and EV71 Pevear et al., 1999; Shia et al., 2002) .
Pleconaril is now licensed by Schering-Plough (since 2003) and has been investigated for the treatment of HRV-induced exacerbations of asthma and chronic obstructive pulmonary disease in high-risk patients (http://www.clinicaltrials.gov; NCT00394914), and for the treatment of neonatal sepsis (http://www.clinicaltrials.gov; NCT00031512). Its potential use in the treatment of these diseases warrants investigation of the underlying mechanisms of resistance emergence. Furthermore, understanding the mechanisms underlying resistance to capsid inhibitors is crucial for the development of new and improved anti-EV drugs.
Previous in vitro studies showed that echovirus 11 (E11) isolates are among the strains most susceptible to pleconaril . We identified the first pleconaril-resistant E11 strain from an immunodeficient patient with chronic meningoencephalitis, who had been treated with IVIg for over 40 years and only recently with pleconaril. The patient was unresponsive to IVIg or pleconaril (Wildenbeest et al., 2012) . E11 resistant strains were already present before the patient had been treated with pleconaril, excluding the possibility that the resistance was drug induced. Here, we investigated the underlying mechanisms of this intrinsic resistance.
RESULTS

Pleconaril susceptibility and IVIg titres of the patient strains and clinical isolates
Three pleconaril-resistant E11 strains were identified from one patient who had been treated with IVIg over a number of years, and with pleconaril in 2008 (Wildenbeest et al., 2012) . The three strains, collected in the years 2007, 2008 and 2009 , were resistant to pleconaril and were neutralized 
Hydrophobic pocket topology and pleconaril docking
To determine the pocket topology, three-dimensional models of the P1 asymmetrical unit of the resistant strain M07067754 and the susceptible clinical strain 20750473 were compared with structure of the prototype strain (PDB 1H8T) ( Fig. 2 ) (Stuart et al., 2002) . Both E11-PT and 20750473 displayed a similar pocket topology (Fig. 2) . In contrast, the pocket topology for M07067754 had been altered, disabling efficient docking within the pocket of M07067754. The inefficient docking was corroborated by the PEARL interaction energy values for pleconaril (Table  2) . Values for the sensitive E11-PT and 20750473 indicated a strong interaction of pleconaril within the pocket in comparison with the interaction of pleconaril within the pocket of the resistant patient strain M07067754 (Table 2) . These interactions were underlined by lower interaction values of the pocket factor in E11-PT and 20750473, indicating that pleconaril binding within the pocket was favoured over the pocket factor and therefore outcompeted the pocket factor. In contrast, pleconaril values were lower compared with the pocket factor in M07067754, so pleconaril was predicted not to outcompete the pocket factor in this strain.
Amino acid substitutions lining the hydrophobic pocket
Pleconaril docks within a hydrophobic pocket formed within the capsid. Therefore, amino acid substitutions conferring pleconaril resistance are likely to be located within the pocket. The models suggested that the amino acids that line the pocket are found predominantly in VP1 (black bordered boxes in Figs 3 and S2, available in the online Supplementary Material). In total, 33 residues in VP1 displayed substitutions that were specific for the patient strains compared with the clinical and prototype strains (Fig. S1, red boxes) . None of the substitutions was identified as a culture artefact, as similar residues were identified in the original cerebrospinal fluid (CSF) specimens of the patient. Of these 33 residues, three residues E11-PT 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 Characterization of echovirus 11 pleconaril resistance (V117I, V119M and I188L) were identified as being involved in formation of the hydrophobic pocket and thus could confer resistance to pleconaril (Figs 2 and 3) . Modelling of V117I and V119M showed inefficient lining of the pocket at the site of these residues in M07067754, most probably due to the protruding sulfate side chain of methionine. Substitution I188L was involved in pocket formation; however, no hindrance of docking could be attributed to this residue. The substitution V117I was identified in VP1 sequences published in GenBank, including genogroup G strain E11-NL24/ns/CY/07 (Fig.  S1 ). The V119M and I188L substitutions were not found in published sequences.
Pleconaril-induced resistance
To assess whether the amino acid mutations observed in vivo could be induced under drug selection, the sensitive clinical strain 20750473 was cultured with increasing concentrations of pleconaril. Resistance to pleconaril was already observed by passage 3 (strain 3A4), displaying an increase in IC 50 of 1 mM. At passages 4-6, the IC 50 was ¢32 mM, confirming that resistance was induced (Table  3) . Modelling of the resistant variant at passage 6 [strain B3 (6B3), Fig. 2 ] showed a similar pocket topology as shown for the sensitive strains E11-PT and 20750473, yet docking of pleconaril within the pocket was inefficient, most likely due to the loose structure of the pocket surrounding pleconaril. Similar data were found for the resistant strain B5 at passage 11 (strain 11B5; data not shown). As indicated for the sensitive E11-PT and resistant M07067754 strain, PEARL energy values for pleconaril interaction of the parental strain and strain 6B3 were comparable, underlying the susceptibility difference in vitro (Table 2) .
Comparison of the amino acid sequence showed an I183M substitution after three passages (strain 3A4) and this was retained in further passages (Table 3) . Interestingly, residue 119 containing the VAM change in the patient strain was also found to be substituted in vitro when pleconaril was omitted (V119I). Strain 11B5 containing the V119I substitution was shown to replicate more efficiently that the strain at passage 6 (6B3) (data not shown), suggesting a compensatory function of this substitution. IVIg was able to neutralize both the parental sensitive clinical strain and the in vitro-induced resistant strain 6B3 with titres of 32 ( Table 3) . Modelling of the I183M substitution suggested that the substitution most likely conferred resistance by the protruding sulfate side chain of methionine.
Residues lining the hydrophobic pocket confer resistance
To assess the precise contribution of the substitutions predicted to line the hydrophobic pocket of the patient strain (V117I, V119M and I188L) and the in vitro-induced pleconaril-resistant strains (V119I and I183M), all five mutations were introduced into a sensitive E11 clone (Table 4) . Of the seven mutant clones, four produced viable virus, three containing the single mutation V117I, V119M or I188L and one containing the double mutation V119M and I188L. Clones carrying the V119I and I183M mutations were not viable. The single mutant clones containing the V117I and I188L mutation were found to be sensitive to pleconaril, whereas the single and double mutant clones containing the V119M mutation were resistant. As the single mutant containing the I188L substitution did not confer resistance on its own, resistance in the double mutant was suggested to be conferred primarily by the V119M mutation. IVIg was able to neutralize all four clones with comparable neutralizing titres ( Table 4 ).
The V119I clones were not viable to confirm the compensatory function of this mutation in vitro.
DISCUSSION
Currently, pleconaril is being reinvestigated for the treatment of HRV-induced exacerbations of asthma and chronic obstructive pulmonary disease in high-risk patients and neonatal sepsis (http://www.clinicaltrials.gov; NCT00394914 and NCT00031512, respectively). It is therefore important to understand the underlying mechanisms of susceptibility and emergence of resistance, in particular of clinical isolates. Our study investigated the genetic and molecular structural basis for pleconaril resistance in the intrinsically susceptible E11 genotype, of which we here describe a resistant strain isolated from a patient before pleconaril treatment was started.
In concordance with the phenotypic susceptibility, structural modelling and interaction predictions depicted inefficient docking of pleconaril for the pleconaril-resistant patient strain M07067754, whilst pleconaril was shown to dock efficiently within the pockets of the susceptible prototype and clinical strains. The basis for resistance of pleconaril involves amino acids lining the hydrophobic pocket (Heinz et al., 1989) . Sequence analysis of the capsid region revealed that three residues involved in pocket topology had been substituted in the resistant strain; V117I, V119M and I188L. Modelling suggested that V119M conferred resistance, most probably due to the protruding sulfate side chain of methionine, whereas no hindrance of pleconaril docking could be attributed to V117I and I188L. Notably, pleconaril resistance induced in vitro in a susceptible E11 clinical isolate was underlined by a different substitution (I183M), albeit by similar mechanisms. The different markers corroborated that pleconaril resistance in vivo was not pleconaril induced, suggesting that other factors underlie the intrinsic resistance found in vivo. Taking into account the immunological divergence of the patient strain, the V119M substitution could have been induced immunologically. The V119M substitution is suggested to account for one of the multiple changes required for immunological divergence, as the clone carrying the V119M substitution alone did not indicate alteration in IVIg susceptibility. Unfortunately, we did not have access to additional historical strains of the patient to determine whether the patient was already infected with this antigenically divergent strain or whether resistance developed under immune selection pressure by the longterm duration of IVIg treatment. Nonetheless, as the other genogroup G strain, E11-NL24/ns/CY/07, did not carry the resistant V119M substitution, we suspect this substitution to have been acquired during replication under IVIg treatment within the patient. Additional studies are required to investigate the role of immunological divergence in affecting drug susceptibility.
In summary, this study indicates that different markers may underlie resistance occurring against a capsid inhibitor in circulating patient strains or those induced in vitro. This is crucial to take into account when developing new drugs.
Our data indicate the importance of investigating susceptibility differences against potential anti-picornaviral drugs, (Benschop et al., 2010) . As control viruses in the pleconaril inhibition assays and IVIg neutralization, E13 (Wildenbeest et al., 2012) , CVA9, CVB3, EV71 (RIVM) and HRV16 (a gift from Dr K. van der Sluijs, Laboratory of Medical Immunology, Academic Medical Center, Amsterdam, The Netherlands) were used. The E11 clone was a kind gift from Dr P. Susi (University of Turku, Turku, Finland).
Pleconaril inhibition assay and virus neutralization. The pleconaril inhibition assay and IVIg neutralization was performed as described previously (Wildenbeest et al., 2012) . Pleconaril susceptibility was expressed as the IC 50 Wildenbeest et al., 2012) . Neutralizing antibody titres within IVIg were calculated by end-point neutralization.
RNA isolation and 5 §-untranslated region-based real-time PCR.
All isolates (20 ml) and clinical samples (200 ml) were extracted using a MagnaPure LC instrument (Roche Diagnostics). RNA was eluted in 50 ml elution buffer and reverse transcribed and detected by EV realtime PCR as described previously (Benschop et al., 2008a (Benschop et al., , b, 2010 .
RT-PCR of VP1 and the complete capsid gene. The culture isolates and clinical samples were VP1 genotyped using the seminested EV-B-CSF assay of McWilliam Leitch and co-workers (Kroneman et al., 2011; McWilliam Leitch et al., 2009) . The VP1 sequences of the E11 clinical strains were compared with VP1 sequences of the E11 dataset published by McWilliam Leitch et al. (2010) . Sequences were aligned using CLUSTAL W implemented in SSE (Simmonds & Smith, 1999) . Bootstrapped (1000 replicates) maximum-likelihood trees were generated using MEGA5 (Kumar et al., 2004) with pairwise deletion for missing data and a gamma distribution value of 0.8 (McWilliam Leitch et al., 2010) .
The complete capsid P1 sequence was amplified by generating overlapping regions (primers are available upon request). The complete capsid region was aligned using SSE (Simmonds & Smith, 1999) .
Site-directed mutagenesis. Seven mutant E11 clones were constructed by site-directed mutagenesis (QuikChange II XL; Agilent Technologies). The clones contained single, double or triple mutations at residues 117, 119 and 188 (Table 3 ). The clones were linearized by digestion with XhoI, and RNA was transcribed with T7 RNA polymerase (MEGAscript T7 kit; Ambion). The RNA was transfected into Vero cells using the X-tremeGENE transfection reagent (Roche Applied Science). The supernatant was titrated by the TCID 50 method of Reed & Muench (1938) and sequenced for verification.
In vitro isolation of drug-resistant mutants. A pleconaril-sensitive E11 clinical strain (20750473, 100 TCID 50 in 50 ml) was incubated in 10-fold dilutions of pleconaril (100-0.0001 mg ml 21 ) in duplicate in Eagle's minimal essential medium (EMEM)/2 % FCS for a maximum of 7 days. The virus growing at the maximum pleconaril concentration was passaged further with pleconaril in 10-fold dilutions (100-0.0001 mg ml
21
) in duplicate in EMEM/2 % FCS. This process was repeated for six passages, after which the virus was passaged a further five times without pleconaril. For each passage, the viral isolates were stored at 220 uC for VP1 sequencing and in vitro susceptibility testing.
In silico modelling of the VP1-4 complex encoded by the P1 gene. Amino acid sequences of VP1-4 of the E11-PT strain were submitted to I-TASSER (Zhang, 2008) providing PDB entry 1H8T (Stuart et al., 2002) as the user-supplied template structure for combined ab initio and homology modelling. The top threedimensional models of VP1-4 [judged by TASSER C-scores and structure similarity with echovirus VPs assayed by MATRAS (Kawabata, 2003] were projected onto the known structure of the echovirus VP1-4 complex to create a three-dimensional model of the asymmetrical unit of the EV capsid. Steric clashes were removed via CHIRON (Ramachandran et al., 2011) . The three-dimensional structure of pleconaril was taken from PDB 1C8M. Docking of pleconaril was carried out by PATCHDOCK (Schneidman-Duhovny et al., 2005) . The PATCHDOCK top 20 results were ranked according to their energy profiles determined by means of PEARLS in order to select the most stable complex (Han et al., 2006) . Pockets were identified by POCKETFINDER (Laurie & Jackson, 2005) . RASTOP, CHIMERA (Pettersen et al., 2004) and the PDBsum facility of PROFUNC (Laskowski et al., 2005) were used to display the figures.
